Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Using zebrafish, researchers at the University of Pittsburgh have identified and described an enzyme inhibitor that allows them to increase the number of cardiac progenitor cells and therefore influence the size of the developing heart. The findings were described online in Nature Chemical Biology on July 5.


During this week's podcast Dr. Michael Tsang takes a close look at the key findings of the research group and talks about the main implications of the study for research on the heart. He also discusses why the zebrafish was a good model for this work.


While the discovery is particularly relevant for cardiology, Dr. Tsang goes onto to explain the importance of the study for wound healing as well. He also provides details on plans for future experiments that are designed to move this research forward.
Michael Tsang, Ph.D., has been an assistant professor in the Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, since 2004 and a member of the university's Drug Discovery Institute since 2008. His research focuses on understanding the developing embryo, primarily through study of zebrafish, vertebrates whose transparent embryos are carried outside the mother. Dr. Tsang completed his postdoctoral training at the National Institute of Child Health and Human Development. He received his doctorate in 1996 and his Bachelor of Science (Hons.) in pharmacology in 1992 from University College Dublin, Ireland.


  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »